Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Recipharm and Pharmanest Form Collaboration

Published: Friday, July 04, 2014
Last Updated: Friday, July 04, 2014
Bookmark and Share
New pharmaceutical manufacturing contract for commercial manufacture and supply of SHACT.

Recipharm Karlskoga AB and Pharmanest AB have announced the formation of a new pharmaceutical manufacturing contract for SHACT.

Every year, millions of women around the world experience pain and discomfort during IUD insertion (intrauterine contraception). There are few treatment options with proven efficacy and safety available to these women.

SHACT is a product based on an innovative formulation of lidocaine, a well-known anesthetic, and a proprietary application device developed to simplify topical application in the cervix and uterus.

SHACT has demonstrated convincing Phase II efficacy data as local anesthesia in connection with IUD insertion and also recently reported positive data from a hysteroscopy study.

Recipharm and Pharmanest have reached a milestone in their existing collaboration and Pharmanest is now preparing its candidate SHACT for launch.

Additionally, the companies have reached a long term agreement for commercial manufacturing, with the precise product launch date to be announced later.

Jointly, the two companies will offer commercial supply to any market that Pharmanest determine to enter for supply and sales of their first pharmaceutical product SHACT.

Ingela Palmkvist, General Manager at Recipharm in Karlskoga, commented: “I really look forward to closely following the introduction of this product to various markets. Indeed, I believe it will make a highly significant difference to patients.”

Gunilla Lundmark, CEO at Pharmanest said: “I am very pleased that Pharmanest and Recipharm have entered into this new collaboration following the product development success achieved to date. Given the strong clinical data we are now rapidly moving toward commercialization. We look forward to working closely with Recipharm for the commercial manufacture of the product and, indeed, to pooling our respective skills and capabilities to supply the pharmaceutical product to key target markets.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Recipharm Announces Global Serialisation Collaboration
Company has announced partnership with Marchesini, SEA Vision and TraceLink to introduce new serialisation capabilities.
Thursday, June 23, 2016
Recipharm Unveils Serialisation Pricing Model
Company has unveiled plans to improve the affordability of serialisation, with the introduction of a novel pricing model aimed at keeping investment costs down for clients.
Tuesday, May 31, 2016
Recipharm Acquisitions Create Global CDMO Leader
Recipharm has announced that it has signed two separate agreements to acquire Kemwell’s pharmaceutical contract development and manufacturing (CDMO) businesses.
Tuesday, April 19, 2016
Recipharm Takes the Lead in Serialisation Challenge with €40m Investment
The company has unveiled that it plans to invest €40m over the next three years to ensure solutions for serialisation processes.
Thursday, February 11, 2016
Recipharm Presents 2016 International Environmental Award Winner
Jerker Frick won the award in recognition of his research into the environmental effects of pharmaceuticals.
Tuesday, February 02, 2016
Recipharm Appoints New Key Account Director for Europe
Company announces appointment of Anke Mollowitz.
Thursday, January 21, 2016
Recipharm Appoints General Manager
Company appoints Yves Buelens for its new blow fill seal subsidiary in Kaysersberg, France.
Saturday, January 09, 2016
Recipharm Signs Manufacturing Agreement with Alcon
Company acquires facility in France, adding new niche capabilities.
Tuesday, December 22, 2015
Recipharm and LIDDS Sign Contract
Contract for production of Liproca® Depot and investment in LIDDS.
Thursday, December 17, 2015
Recipharm Secures €25 Million Contract with Daewoong Pharmaceutical
Company has signed an agreement with Daewoong for the manufacture and supply of Erdosteine API.
Tuesday, November 24, 2015
Recipharm Announces Signing of an Agreement with Daewoong
Company secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical.
Saturday, November 14, 2015
Recipharm to Acquire Majority Stake in Indian CMO Nitin Lifesciences
Company enters into an agreement to acquire Indian sterile injectables CMO, Nitin Lifesciences.
Wednesday, October 28, 2015
Recipharm Appoints New Business Director for Italy
Company also appoints new General Manager at Pessac, France.
Tuesday, October 27, 2015
Recipharm Reaches Agreement with LobSor Pharmaceuticals
Agreement to manufacture LECIGON™, a proprietary treatment for advanced Parkinson’s disease.
Thursday, September 10, 2015
Recipharm Signs Agreement with RedHill Biopharma
Agreement for manufacturing of RHB-105 for treatment of H. pylori infection.
Thursday, August 27, 2015
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
A New Way Out for Stem Cells
Researchers at North Carolina State University have discovered that therapeutic stem cells exit the bloodstream in a different manner than was previously thought.
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
Designing Potential AIDS Vaccine Candidates
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Anticancer Drug Stops Ebola Virus Molecule in its Tracks
A team of scientists from the University of Oxford have successfully mapped the structure of the Ebola virus molecule that drives the attack strategy and leads to fatal infections in humans.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!